IPG PHOTONICS CORP (IPGP): what the price assumes

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/IPGP

Headline

Field	Value
Ticker	IPGP
Company	IPG PHOTONICS CORP
Current price	$80.78/sh

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin (value-band context)	15.8%
Operating margin (mid-cycle)	17.9%
Margin compression (value-band)	-2.1pp
Trailing margin (depressed year)	0.3%
Implied growth	21.9%
Multiple paid	16x mid-cycle operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 11.2% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.5pp.

Reconcile: at the x-ray's 9.3% required return this reads ~9.5%/yr; the models below use their own rates.

How unusual the bet is: within-range

Reference	Value
vs own history	+0.06σ
sustained it ~5 years at this level	39%
implied end-window share	0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	7.01x	2	expensive
Earnings	6.97x	2	expensive
Relative	2.64x	3	expensive
Growth	1.67x	2	expensive

Families that call it expensive: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=9)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$37.84	2.13x	yes	Reference only (OCF-based, capex excluded): OCF $0.1B
DCF Exit Multiple	Growth	$0.00	—	no	Negative/zero FCF or EBITDA — equity value floored at $0
Relative Valuation	Relative	$30.61	2.64x	yes	P/E 48.4x (blended: static sector reference 22x + trailing (TTM) 120x), scenarios: 40.4x / 48.4x / 56.4x (bear / base = reference held flat / bull), EV/EBITDA 35.2x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$7.29	11.08x	yes	BV/sh $49.31, ROE (TTM) 1.4%, ke 9.3%
Two-Stage Excess Return	Asset	$3.93	20.55x	yes	5yr excess ROE then converge to ke=9.3% (excluded from median)
Discounted Future Market Cap	Growth	$67.20	1.20x	yes	Rev $1.0B, growth 10% (input: historical growth; tapered), Terminal P/S: 2.8x / 3.3x / 3.9x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/E	Relative	—	—	no	—
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$27.41	2.95x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $0.10B × (1−21%) / WACC 9.1% → EPV (no growth)
Residual Income	Asset	$2.82	28.65x	yes	BV $49.31 + 5yr PV of (ROE (TTM) 1.4% − Kₑ 9.3%) × BV; BV grows 0.9%/yr (excluded from median)
Graham Number	Asset	$27.47	2.94x	yes	√(22.5 × EPS $0.68 × BVPS $49.31) — Graham's conservative floor
EV/EBITDA Relative	Relative	$16.70	4.84x	yes	EBITDA $0.02B × sector EV/EBITDA 16.0x
FCF Yield	Earnings	—	—	no	—
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	$3.27	24.70x	yes	EPS $0.68 × (8.5 + 2×-1.4%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/B	Asset	—	—	no	—
P/Sales Sector	Relative	$121.35	0.67x	yes	Revenue $1.04B × sector P/S 5.0x
PEG Fair Value	Relative	—	—	no	—
Earnings Yield	Earnings	$7.35	10.99x	yes	EPS $0.68 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net cash	$812.9m
Net debt / NOPAT (after-tax)	-5.52x (net cash)
Net debt / operating income (pre-tax)	-4.36x (net cash)
Share count CAGR (buyback)	-5.2%
Burning cash	no

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 17.9%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• IPG Photonics is the leading maker of high-power fiber lasers, the industrial tools that cut, weld, and clean metal, with roughly 86% of revenue from the cyclical materials-processing market.
• The balance sheet is the standout: about $813 million of net cash, no debt, and a share count shrinking around 5% a year as the company buys back stock.
• The tension is that earnings are at a cyclical trough, trailing operating income is barely positive, yet the price sits above every valuation method, so the buyer is paying for a recovery that has not yet shown up in profit.

Bull Case

Start with the balance sheet, because for a deeply cyclical industrial it is the difference between weathering a downturn and being forced into one. IPG Photonics holds roughly $813 million of net cash and carries no debt at all. That is an extraordinary cushion for a company whose end markets swing hard: it means IPG can keep funding research, keep its factories staffed, and keep buying back stock straight through a trough that would force a leveraged competitor to retrench. The share count has fallen about 5% a year, so the company is shrinking the equity base while it waits for the cycle to turn, which concentrates the eventual recovery into fewer shares.

The technology position is genuine. IPG pioneered the high-power fiber laser and remains the volume leader, with vertically integrated manufacturing of its own components, which gives it a cost and reliability edge that pure assemblers lack. Fiber lasers have been steadily displacing older laser and mechanical cutting tools because they are more efficient and more precise, and the most recent quarter showed the demand cycle beginning to recover: revenue rose 17% year over year to $265.5 million, driven by Industrial Solutions, especially welding and battery-related applications, with a book-to-bill ratio above 1 for a second straight quarter. A book-to-bill above 1 means orders are outrunning shipments, the early signal of an upturn.

The company also cleared a long-running overhang. IPG reached a global agreement with TRUMPF to resolve and dismiss all patent litigation between the two laser leaders worldwide, removing a source of legal cost and uncertainty. The bull case is straightforward: a debt-free technology leader at a cyclical low, buying back its own stock, with orders turning up and a major legal dispute settled. If the materials-processing cycle recovers toward its normal level, the earnings power that is invisible at the trough comes back into view.

Bear Case

The structural truth a holder has to face is that IPG Photonics barely earns a profit right now, and the price is paying as if the recovery is already banked. Trailing operating income is only marginally positive, an operating margin near breakeven, and yet no family of valuation method, asset value, earnings power, peer multiples, or even forward growth, reaches the current price. When even the optimistic growth method lands below the price, the market is pricing a bet beyond what any standard frame supports: a full-cycle recovery, on the timeline and to the magnitude the bull hopes for, with little room for it to disappoint.

The concentration in one cyclical market is the core vulnerability. The 10-K states that roughly 86% of revenue comes from materials processing, where sales "are cyclical and have historically experienced sudden and severe downturns and periods of oversupply". That is the company describing its own demand profile as prone to crashing without warning. A buyer at today's price, which already embeds a recovery, is exposed to exactly the kind of sudden reversal IPG itself warns is normal for the category.

Competition is intensifying in a way that pressures the very margins the recovery is supposed to restore. The 10-K notes that customers have "developed products for their own use which are competitive to our products" and that fiber-laser rivals are "increasing the output powers of their fiber lasers and reducing sales prices to compete". Lower-cost competition, much of it from China, has been eroding IPG's pricing power for years, which is part of why the trailing margin sits so far below the company's historical peak. Even in the recovering quarter, adjusted gross margin contracted on tariff and product-cost headwinds. The balance sheet is a fortress, so this is not a solvency bear. It is a valuation bear: the price assumes a clean cyclical recovery to former margins, while competition and pricing pressure may mean the next peak is lower than the last.

Valuation

IPG Photonics is the textbook trough-earnings problem: the business is at a cyclical low, so the trailing numbers understate its normal earning power, yet the price already sits above every method, which means the market is pricing the recovery rather than the trough. Invert the price and it requires the company to lift operating margins toward roughly 29% over the next several years, against a trailing margin near breakeven. That is a full-cycle recovery assumption, stated plainly.

The methods are unanimous, and that unanimity is the signal. No family reaches the price. The asset-based and earnings-power lenses sit far below it because at trough earnings there is little profit to capitalize, and even the forward-growth method lands under the price. When every method says expensive and the price holds, the buyer is paying for a return to a normalized, mid-cycle margin the company has earned before but is not earning now. The spread between price and method is the recovery premium, and the risk is that competition and pricing pressure mean the next peak margin is lower than the last.

Solvency is the part that makes the wait survivable, and it is genuinely strong. IPG holds about $813 million of net cash, carries no debt, and has been shrinking its share count roughly 5% a year. A debt-free balance sheet at a cyclical trough is the ideal position: the company can keep investing and buying back stock while weaker competitors retrench, so when demand recovers, the earnings rebound lands on a smaller share base. The decisive variable is not the balance sheet, which is a fortress; it is whether the materials-processing cycle recovers to the margins the price assumes, and whether competition lets those margins return.

Catalysts

The most recent quarter, the first of 2026, was the clearest sign yet of a cyclical turn. Revenue rose 17% year over year to $265.5 million, ahead of forecasts, driven by Industrial Solutions, especially welding and battery-related applications, and the book-to-bill ratio stayed above 1 for a second straight quarter, meaning orders outran shipments. Net income was held down to $1.6 million by a $13.5 million litigation settlement charge, and adjusted gross margin contracted to 37.8% from 40.0% on tariff and product-cost headwinds.

The company also removed a major overhang by reaching a global agreement with TRUMPF to resolve and dismiss all patent litigation between the two laser leaders worldwide. For the second quarter, IPG guided to revenue of $260 million to $290 million and adjusted EPS of $0.25 to $0.55.

The forward watch items are the durability of the order recovery and the path of margins. A book-to-bill above 1 supports a favorable near-term outlook, but tariff and cost pressures are squeezing gross margin even as volume returns. Raymond James cut its rating from strong-buy to outperform, a reminder that the recovery is priced in. Each subsequent quarter tests whether the upturn is sustained and whether margins can recover alongside volume.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• COHR (COHERENT CORP.)
• FY2025 10-K: …and display capital equipment verticals in the industrial end market. Gross margin. Gross margin for the year ended June 30, 2024 was $1,456 million, or 31%, of total revenues, compared to $1,618 million, or 31% of total revenues, for fiscal 2023, a slight decrease of 43 basis points. During fiscal 2023, the Company…
• FY2025 10-K: …$ 14 million and $ 24 million, respectively. 78 Note 14. Segment and Geographic Reporting Our Chief Executive Officer has been identified as the chief operating decision maker ("CODM") as he utilizes financial information to make decisions about allocating resources and assessing performance for the entire Company,…
• LASR (NLIGHT, INC.)
• FY2025 10-K: …that offer semiconductor lasers, fiber lasers, fiber amplifiers and other laser products such as IPG Photonics, Coherent, BWT Ltd., Raycus Fiber Laser Technologies, and Trumpf GmbH + Co. KG. We also compete with prime defense contractors and subcontractors in the Aerospace and Defense market, and with companies in…
• FY2025 10-K: …consisting of the Laser Products segment and the Advanced Development segment. We organize our business segments based on the nature of products and services offered. Laser Products This segment includes high-power semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing…
• LITE (Lumentum Holdings Inc.)
• FY2025 10-K: …our revenue and margins, or, if the ongoing relationship no longer benefits us, we may decide to suspend or terminate our relationship with such customers. There are also continuing trade tensions, including an uncertain regulatory environment, in the U.S. and countries in Asia, and in particular, China, which have…
• FY2025 10-K: …• our introduction of new products and enhancements, or entry into new markets with different pricing and cost structures. We have also seen, and may continue to see, our gross margins negatively impacted by increases in component costs, logistics costs, elevated inventory balances, and pricing pressure. Failure to…
• MKSI (MKS INC)
• FY2025 10-K: …harmed. We operate in highly competitive markets characterized by rapid technological advances, frequent product introductions and enhancements, changing customer requirements, evolving industry standards, substantial capital investment and increasing price pressure. Our success depends upon our ability to…
• FY2025 10-K: …rapid demand shifts, the semiconductor capital equipment industry has recently been subject to significant trade restrictions, especially in key markets, including China. Approximately 43% and 42% of our net revenues for 2025 and 2024, respectively, were from sales to customers in the semiconductor market. Net…
• AEIS (ADVANCED ENERGY INDUSTRIES INC)
• FY2025 10-K: …operations, before income tax ​ 168.7 ​ 9.4 ​ ​ 52.4 ​ 3.5 ​ Income tax provision (benefit) ​ 19.4 ​ 1.1 ​ ​ (3.9) ​ (0.3) ​ Income from continuing operations ​ $ 149.3 ​ 8.3 % ​ $ 56.3 ​ 3.8 % ​ ​ 36 Table of Contents Revenue The following tables summarize net revenue and percentages of revenue by markets: ​ ​ ​ ​ ​…
• FY2025 10-K: …risks related to our reliance on our intellectual property. 8 Table of Contents Competition The markets we serve are highly competitive and characterized by rapid technological development and changing customer requirements. We face a wide variety of competitors, and no single company dominates any of our markets.…
• ICHR (Ichor Holdings, Ltd.)
• FY2025 10-K: …support future growth. In addition to providing high quality and reliable fluid delivery subsystems and components, one of our principal strategies is delivering lead-times that provide our customers with the required flexibility needed in their production processes. We have accomplished this by investing in scalable…
• FY2025 10-K: …devote greater resources to the development, promotion, sale and support of their products and services, and reduce prices to increase market share. In addition to organic growth by our competitors, there may be merger and acquisition activity among our competitors and potential competitors that may provide our…
• UCTT (Ultra Clean Holdings, Inc.)
• FY2025 10-K: . Although some of our business, including the cleaning, coating and analytical services that support the semiconductor chip market, are less susceptible to such fluctuations, recurring slowdowns in the industries we serve have historically had adverse effects on our overall operating results. Demand shifts in these…
• FY2025 10-K: …effectiveness, we have expanded our total available market significantly. • Develop or acquire solutions that allow our customers to succeed at the leading edge of the semiconductor processing nodes . Leveraging our technology roadmap assessments and broad customer engagements, we continue to expand the number and…
• FORM (FormFactor, Inc.)
• FY2025 10-K: …new products that will be competitive with ours. New alternatives to our products may also be introduced, by our current competitors or others, which may reduce the value of one or more of our products. Semiconductor manufacturers may implement chip designs that include capabilities or use other methodologies that…
• FY2025 10-K: MPI Corporation, Shenzhen Senmeixieer Technology Co., Ltd ("Semishare"), STAr Technologies, Inc., Tokyo Electron Limited ("TEL"), and Wentworth Laboratories, Inc. We believe that the primary competitive factors in the probe station market are measurement accuracy and versatility at temperature, including cryogenic…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

IPG Photonics FY2025 10-K · IPG Photonics Q1 2026 earnings release · IPG Photonics Q2 2026 guidance